Related Experiment Videos
GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study
Marie Vu1, Madelyn Schmidt2, Smiti Gandhi2
1Department of Dermatology, University of Texas Medical Branch, Galveston, Texas.
Summary
Glucagon-like peptide-1 (GLP) receptor agonists reduce inflammatory complications after dermatologic surgery. These GLP drugs, including semaglutide and tirzepatide, show promise for improved wound healing and patient safety.
Area of Science:
- Dermatology
- Pharmacology
- Surgical Outcomes
Background:
- Glucagon-like peptide-1 (GLP) receptor agonists possess known anti-inflammatory and wound-healing properties.
- The effect of GLP receptor agonists on outcomes following dermatologic surgery remains uninvestigated.
Purpose of the Study:
- To evaluate the one-month risk of postoperative inflammatory complications (IC) in patients using GLP receptor agonists.
Main Methods:
- A retrospective cohort study using the TriNetx Research Network.
- Identified patients undergoing Mohs Micrographic Surgery or wide local excisions for skin cancer on GLPs (semaglutide, tirzepatide, liraglutide, etc.).
- Analyzed IC including wound disruption, hematoma, infection, and other procedural complications, adjusting for demographics and comorbidities.
Main Results:
- GLP receptor agonist use was linked to a significantly lower risk of postoperative infections, wound disruption, hematoma, and other complications.
- Semaglutide and tirzepatide showed the most substantial reductions in postoperative complications among individual GLPs.
Conclusions:
- GLP receptor agonists are associated with a reduced risk of postoperative inflammatory complications after dermatologic procedures.
- These findings support the perioperative safety of GLP receptor agonists and suggest a potential benefit in wound healing.
